The Evolutionary History of Amino Acid Variations Mediating Increased Resistance of S. aureus Identifies Reversion Mutations in Metabolic Regulators

Mia D. Champion1,a, Vanessa Gray1,b, Carl Eberhard2,c, Sudhir Kumar1

1 Center for Evolutionary Medicine & Informatics, Biodisgn Institute, Arizona State University, Arizona, United States of America, 2 Division of Pathogen Genomics, Translational Genomics Research Institute, Arizona, United States of America

Abstract

The evolution of resistance in Staphylococcus aureus occurs rapidly, and in response to all known antimicrobial treatments. Numerous studies of model species describe compensatory roles of mutations in mediating competitive fitness, and there is growing evidence that these mutation types also drive adaptation of S. aureus strains. However, few studies have tracked amino acid changes during the complete evolutionary trajectory of antibiotic adaptation or been able to predict their functional relevance. Here, we have assessed the efficacy of computational methods to predict biological resistance of a collection of clinically known Resistance Associated Mutations (RAMs). We have found that >90% of known RAMs are incorrectly predicted to be functionally neutral by at least one of the prediction methods used. By tracing the evolutionary histories of all of the false negative RAMs, we have discovered that a significant number are reversion mutations to ancestral alleles also carried in the MSSA476 methicillin-sensitive isolate. These genetic reversions are most prevalent in strains following daptomycin treatment and show a tendency to accumulate in biological pathway reactions that are distinct from those accumulating non-reversion mutations. Our studies therefore show that in addition to non-reversion mutations, reversion mutations arise in isolates exposed to new antibiotic treatments. It is possible that acquisition of reversion mutations in the genome may prevent substantial fitness costs during the progression of resistance. Our findings pose an interesting question to be addressed by further clinical studies regarding whether or not these reversion mutations lead to a renewed vulnerability of a vancomycin or daptomycin resistant strain to antibiotics administered at an earlier stage of infection.

Introduction

Within a decade following the accidental discovery of penicillin G, the majority of known S. aureus isolates produced a β-lactamase enzyme mediating resistance to the antibiotic [1]. This led to the development of a more effective antimicrobial (β-lactamase-resistant β-lactam methicillin), an effort that was counteracted by methicillin resistant S. aureus (MRSA) [1,2]. The rapid and prolific emergence of resistance has diminished the effectiveness of every tested class of antibiotics to date, including vancomycin and daptomycin [1–3]. And the phenomenon of cross-resistance has emerged as an important mechanism in the development of pan-resistance to numerous classes of antimicrobials against S. aureus [4]. Reports of daptomycin-resistant S. aureus isolates evolving following exposure to vancomycin treatment are increasing in prevalence and are of great concern since these drugs are “last-line of defense” antibiotics against infection [5,6].

Recent studies of several infectious pathogens have revealed how processes of horizontal gene transfer, recombination, and parallel evolution can lead to sequence variations that give rise to the progression of antibiotic resistance [7–10]. The sequential accumulation of multiple nonsynonymous mutations has also been described, and these acquired mutations can contribute directly to increasing virulence by promoting drug evasion or may act to lower the fitness costs of accumulating such variations (e.g. compensatory mutations) [7–9]. For example, specific genetic mutations in S. aureus that are associated with adaptation to vancomycin or daptomycin exposure have recently been reported, and these studies have also established that the progression of resistance in these isolates is accompanied by phenotypic alterations in virulence [6,11,12]. Lowered daptomycin susceptibility in a set of carefully selected isogenic clinical and laboratory S. aureus strains has been reported to be the consequence of specific mutations in the mprF gene encoding a membrane protein, the (walk (yrG)) gene encoding a sensor histidine kinase, and the rpoB
Table 1. Predictions of Functional Relevance For Positive Control RAMs [9,10] Identified From Clinical or Laboratory-derived Isolates Following Exposure to Vancomycin or Daptomycin.

| Vancomycin/ Daptomycin | Antibiotic Exposure of Clinical/ Laboratory Isolate | Gene | Amino Acid position | MSSA (476) allele | MRSA (SAUSA300) allele | P-MRSA Insensitive/Resistant Allele | Polyphen prediction (filtered alignments) | Polyphen score (filtered alignments) | Polyphen prediction (unfiltered alignments) | Polyphen score (unfiltered alignments) | SIFT prediction | SIFT score | CAROL prediction | CAROL score |
|-------------------------|-----------------------------------------------------|------|---------------------|------------------|-----------------------|----------------------------------------|------------------------------------------|----------------------------------------|------------------------------------------|------------------------------------------|----------------|------------|----------------|-------------|
| A10102                  | Daptomycin                                          | aroH/aroA | 301               | K                 | K                     | R                                      | benign                                   | 0.334                                  | benign                                   | 0.161                                    | Tolerated       | 1.000      | Neutral        | 0.160       |
|                         |                                                     | feoB    | 636               | K                 | K                     | E                                      | benign                                   | Not Scored                             | Not Scored                               | Scored                                    | Deleterious     | 0.000      | 0              | 0.000       |
|                         |                                                     | mprF    | 295               | S                 | S                     | L                                      | benign                                   | 0.227                                  | benign                                   | 0.414                                    | Deleterious     | 0.040      | Neutral        | 0.955       |
|                         |                                                     | SA0754  | 139               | G                 | G                     | S                                      | benign                                   | Not Scored                             | Not Scored                               | Tolerated       | 1.000      | 0              | 0.000       |
| A9299                   | Daptomycin                                          | era/RAS | 185               | H                 | H                     | Y                                      | benign                                   | 1.432                                  | benign                                   | 0.019                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
| A5937                   | Vancomycin                                          | lypP    | 290               | L                 | L                     | F                                      | benign                                   | Not Scored                             | Not Scored                               | Tolerated       | 0.370      | 0              | 0.000       |
|                         |                                                     | rpoB    | 481               | H                 | H                     | Y                                      | benign                                   | 0.046                                  | possibly damaging                       | 1.657                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
| A5948                   | Laboratory-derived series, Daptomycin               | cls2    | 33                | T                 | T                     | T                                      | N                                       | benign                                  | 1.054                                    | benign                                   | 0.122                                    | Deleterious     | 0           | Deleterious    | 0.999       |
|                         |                                                     | mnhC    | 110               | A                 | A                     | E                                      | benign                                   | Not Scored                             | not Scored                              | Deleterious     | 0.000      | 0              | 0.000       |
|                         |                                                     | mprF    | 826               | L                 | L                     | F                                      | benign                                   | Not Scored                             | Not Scored                               | Tolerated       | 1.000      | 0              | 0.000       |
| A6224                   | Vancomycin                                          | dtaA    | 38                | S                 | S                     | R                                      | benign                                   | 1.336                                  | benign                                   | 1.037                                    | Deleterious     | 0.040      | Neutral        | 0.960       |
|                         |                                                     | tllS    | 128               | M                 | M                     | M                                      | I                                       | benign                                  | 0.166                                    | possibly damaging                       | 1.883                                    | Tolerated       | 0.170      | Neutral        | 0.830       |
| A6300                   | Vancomycin                                          | hemL (duplicate copy) | 48 | Y                  | Y                     | Y                                      | D                                       | benign                                  | 0.508                                    | benign                                   | 0.099                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
|                         |                                                     | rpsK    | 127               | R                 | R                     | G                                      | benign                                   | Not Scored                             | Deleterious                             | 0.010                                    | 0            | 0              | 0.000       |
|                         |                                                     | dpr35   | 83                | S                 | S                     | N                                      | benign                                   | 0.038                                  | benign                                   | 0.892                                    | Tolerated       | 0.850      | Neutral        | 0.877       |
|                         |                                                     | hemL    | 48                | D                 | D                     | G                                      | benign                                   | 0.439                                  | benign                                   | 0.235                                    | Tolerated       | 1.000      | 0              | 0.235       |
|                         |                                                     | purD    | 389               | A                 | A                     | V                                      | A                                       | benign                                   | Not Scored                              | Not Scored                              | Tolerated       | 1.000      | 0              | 0.000       |
| A9635                   | Vancomycin                                          | vraG    | 580               | A                 | A                     | V                                      | benign                                   | 0.166                                  | benign                                   | 0.462                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
| A8117                   | Daptomycin                                          | asd     | 94                | N                 | N                     | D                                      | benign                                   | 0.608                                  | benign                                   | 1.453                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
|                         |                                                     | pgsA    | 64                | A                 | A                     | A                                      | V                                       | benign                                   | 0.957                                    | benign                                   | 0.596                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
| A8117                   | Laboratory-derived series, Vancomycin               | walk    | 263               | R                 | R                     | R                                      | C                                       | possibly damaging                       | 1.629                                    | benign                                   | 1.252                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
|                         |                                                     | tcaR    | 69                | S                 | S                     | I                                      | S                                       | benign                                   | 0.355                                    | benign                                   | 0.532                                    | Tolerated       | 1.000      | Neutral        | 0.532       |
| A8796                   | Daptomycin                                          | mprF    | 337               | S                 | S                     | L                                      | benign                                   | 0.585                                  | benign                                   | 0.286                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
|                         |                                                     | citZ    | 221               | G                 | G                     | S                                      | G                                       | benign                                   | 1.032                                    | benign                                   | 0.342                                    | Tolerated       | 1.000      | 0              | 0.342       |
| A8819                   | Daptomycin                                          | cls2    | 60                | F                 | F                     | S                                      | benign                                   | 0.037                                  | benign                                   | 0.849                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
|                         |                                                     | leuS    | 468               | N                 | N                     | N                                      | D                                       | benign                                   | 1.348                                    | benign                                   | 0.131                                    | Deleterious     | 0.000      | Deleterious    | 0.999       |
### Table 1. Cont.

| Vancomycin/ Daptomycin | Antibiotic Exposure of Clinical/ Laboratory Isolate | Gene | Amino Acid position | MSSA (476) allele | MRSA (SAUSA300) allele | P- MRSA Insensitive/ Resistant Allele | Polyphen prediction (filtered alignments) | Polyphen score (filtered alignments) | Polyphen prediction (unfiltered alignments) | Polyphen score (unfiltered alignments) | SIFT prediction | SIFT score | CAROL prediction | CAROL score |
|------------------------|----------------------------------------------------|------|---------------------|-------------------|------------------------|----------------------------------------|-----------------------------------------|-----------------------------------------|------------------------------------------|------------------------------------------|----------------|-----------|-----------------|-------------|
|                        |                                                    |      |                     |                   |                         |                                        |                                        |                                        |                                          |                                          |               |           |                 |             |
| mprF                   | 345                                                | T     | T                   | T                 | T                      | I                        | benign                                  | 0.752                                   | benign                                  | 0.501                                    | Deleterious   | 0.010     | Deleterious     | 0.989       |
| mnaA                   | 302                                                | S     | S                   | S                 | R                      | S                        | benign                                  | 1.043                                   | benign                                  | 1.146                                    | Tolerated     | 0.290     | Neutral         | 0.710       |
| A9635                  | Vancomycin rplC                                    | 7     | G                   | G                 | G                      | V                        | benign                                  | 0.015                                   | possibly damaging                        | 1.538                                    | Deleterious   | 0.000     | Deleterious     | 0.999       |
| A9719                  | Daptomycin cls2                                    | 23    | I                   | I                 | I                      | V                        | benign                                  | 1.375                                   | benign                                  | 0.245                                    | Tolerated     | 0.480     | Neutral         | 0.421       |
| A9754                  | Daptomycin agrC                                    | 58    | S                   | S                 | P                      | S                        | benign                                  | 1.23                                     | possibly damaging                        | 1.714                                    | Tolerated     | 1.000     | Neutral         | 0.000       |
| vqyF                   | 119                                                | W     | W                   | W                 | R                      |                          | probably damaging                       | 2.345                                   | benign                                  | 0.416                                    | Deleterious   | 0.000     | Deleterious     | 0.999       |
| bioF                   | 175                                                | A     | V                   | I                 | V                      |                          | benign                                  | 1.007                                   | benign                                  | 0.452                                    | Tolerated     | 1.000     | Neutral         | 0.452       |
| purA                   | 231                                                | H     | H                   | Y                 | H                      |                          | benign                                  | 0.038                                   | benign                                  | 0.892                                    | Tolerated     | 1.000     | Neutral         | 0.000       |
| rpoB                   | 468                                                | Q     | Q                   | K                 | Q                      |                          | benign                                  | 0.208                                   | benign                                  | 0.066                                    | Tolerated     | 1.000     | Neutral         | 0.065       |
| wdk                    | 471                                                | T     | T                   | I                 | T                      |                          | benign                                  | 0.439                                   | benign                                  | 0.235                                    | Tolerated     | 0.440     | Neutral         | 0.468       |
| A9763                  | Daptomycin cls2*                                   | 52    | A                   | A                 | A                      | F                        | benign                                  | 0.022                                   | probable damaging                       | 2.391                                    | Deleterious   | 0.000     | Deleterious     | 0.999       |
| SA1667                 |                                                   | 54    | H                   | H                 | L                      | H                        | benign                                  | 0.911                                   | benign                                  | 0.875                                    | Tolerated     | 1.000     | Neutral         | 0.875       |
| A9765                  | Daptomycin SA1291                                  | 239   | V                   | V                 | A                      | V                        | benign                                  | 0.144                                   | benign                                  | 1.355                                    | Tolerated     | 0.700     | Neutral         | 0.300       |
| A9781                  | Daptomycin dprA/smf                                | 166   | V                   | V                 | V                      | A                        | benign                                  | Not Scored                              | benign                                  | Not Scored                              | 0              | 0.000     | 0.000           |             |
| pdhA                   | 169                                                | A     | A                   | A                 | T                      |                          | benign                                  | 1.164                                   | NA                                      | NA                                       | Not Scored    | Not Scored | Not Scored      | Not Scored   |
| rpoB                   | 477                                                | A     | A                   | A                 | D                      |                          | benign                                  | 0.035                                   | benign                                  | 0.859                                    | Deleterious   | 0.000     | Deleterious     | 0.999       |
| citZ                   | 222                                                | A     | A                   | T                 | A                      |                          | benign                                  | 0.212                                   | benign                                  | 0.741                                    | Tolerated     | 1.000     | Neutral         | 0.741       |
| SA0248                 | 342                                                | G     | G                   | G                 | C                      | G                        | benign                                  | 0.127                                   | benign                                  | 0.983                                    | Tolerated     | 0.450     | Deleterious     | 0.982       |

(*) indicates P-MRSA to VISA/DRSA amino acid changes according to publicly available sequences, and different from published AA changes. Identified reversion mutations are in bold, italic font. doi:10.1371/journal.pone.0056466.t001
A gene encoding a RNA polymerase subunit [12]. Amino acid variants in several other proteins (vraG, agrA, dltA, rpoB, yvqF, and stp1) acting in multiple genetic pathways have been previously shown to reduce the susceptibility of S. aureus isolates to vancomycin treatment [6,11], and are important regulators of cell wall synthesis and metabolic control [13–16]. Previously identified S. aureus mutations associated with increased resistance have not been evaluated in the context of evolution. In general, neutral evolutionary trends over time help to establish a priori expectations of functional effect because each position in each protein has undergone functional evaluation across evolution [17,18]. As such, Evolutionary Permissible Alleles (EPAs) are predicted as functionally benign whereas damaging predictions are associated with significant adaptions such as those required for acquisition of resistance. Determining positional evolutionary rates of relative allele frequencies constitutes the basis of several in silico prediction methods that have been developed and commonly applied to studies of human genomes in order to provide a diagnosis of a given variation as functionally benign or damaging [19–21].

We have discovered that these prediction methods are significantly inaccurate when applied to diagnosing known RAMs. Furthermore, by tracing the evolutionary history of the false negative RAMs, we have found that these mutations are genetic reversions to conserved ancestral alleles that are carried in a phenotypically methicillin-sensitive isolate (MSSA476). Reversion RAMs are more prevalent in strains exposed to daptomycin treatment and show a tendency to accumulate in enzymes mediating certain reactions of complex biosynthetic pathways. Our findings should therefore be of interest to clinical researchers who have the means to evaluate the relevance of genetic reversions as potential drug targets during the course of treatment.

Results

Failure of Computational Methods to Accurately Predict Resistance Associated Mutations

Evaluation of whole genome S. aureus sequences includes efforts to identify non-neutral sequence changes that are adaptive in the presence of an antibiotic. We therefore adapted popular tools...
PolyPhen, SIFT, and CAROL [19–21] commonly used for this purpose and applied the in silico prediction methods to known RAMs. Performance statistics for accurately predicting known S. aureus RAMs using three commonly used methods (PolyPhen, SIFT, and CAROL) [19–21] (Figure 1A–C) were compared to the accuracy statistics for predictions of Human Disease Associated Mutations (DAMs) [21] using the same computational methods (Figure 1D). Overall, the accuracy of the available tools in predicting RAMs is significantly lower in comparison to predictions of human DAMs (Figure 1D). In order to exclude the possibility that overrepresentation of certain subspecies in the sequence alignments was leading to allele frequency biases that were resulting in false negative predictions, the polyphen analysis was also run with a “filtered alignment” dataset that only included one representative sequence from each closely related bacterial species (Methods). This approach did not significantly improve the number of accurate predictions for the positive control dataset (Table 1). CAROL provides a weighted prediction dependent on PolyPhen and SIFT scores and consistent with the analysis of human variations, the overall prediction accuracy improves when all three tools are used in combination (Figure 1C), thus minimizing the effect of significant spread estimates observed when SIFT and PolyPhen are used independently (Figure 1C) [22,23].

Given the low accuracy of prediction tools in identifying known RAMs, we traced the evolutionary history of the false negative cases and discovered that a significant number are reversion mutations to ancestral alleles, also carried in the genome of the MSSA476 methicillin-sensitive isolate (Figure 2).

False Negative RAMs are Genetic Reversions to Alleles Carried in a Methicillin Sensitive isolate

Approximately 33% of the total positive control RAMs studied are genetic reversions to an allele carried in more ancestral S. aureus strains, including the MSSA476 isolate (Figure 2). Many reversions are also shared with another MRSA isolate lineage, USA300 (FPR3757) (Figure 2, Table 1). A high percentage (>70%) of the RAM reversion mutations exhibit a significant association with non-neutral codons, and therefore are under more significant selective constraints mediating adaptation and fitness (Methods). Both polar and non-polar amino acids revert to MSSA alleles after drug treatment and almost all of them exhibit a neutral side chain charge (Table 1). Independent of the greater total number of variations analyzed from daptomycin-exposed strains, we find a significant presence of reversion allele mutations associated with daptomycin-exposed strains (Fisher’s exact test, p-value < 0.01) in comparison to vancomycin-exposed strains (p-value > 0.5) (Table 1, Figure 2). Reversion mutations accumulate in protein sequences conserved in all strains examined and also arise in one copy of multi-copy proteins (e.g. HemL) (Figure 2). Notably, all of the identified revertant alleles fail to be accurately predicted as functionally damaging by the three methods (SIFT, PolyPhen, and CAROL), with the exception of the agrC and SA0248 reversion RAMs that were accurately predicted by PolyPhen (agrC) or CAROL (SA0248) (Table 1). AgrC encodes a quorum sensing receptor previously shown to mediate S. aureus resistance to deformylase by accumulating mutations compensating for fmt mutations, which reduce bacterial growth rates [15,24]. SA0248 encodes a glycosyl transferase, which transfers sugar moieties to teichoic acids. Predictions from both SIFT and PolyPhen for the amino acid change present in SA0248 following drug exposure

Figure 2. Reversion RAMs accumulate in strains exposed to daptomycin and in one copy of a multicopy protein. Ancestor states for each reversion RAM were determined and mapped onto subspecies phylogenetic reconstructions as described in the methods using MEGA5. Nodes of the tree where mutations occurred in Parental-MRSA (P-MRSA) isolates from patients prior to exposure to daptomycin or vancomycin treatments [11,12] and reverted post-drug treatment to an allele also present in a Methicillin-Sensitive isolate (MSSA476) are annotated. A detailed evolutionary history for protein position 221 of the citZ protein in strain A8796 (treated with daptomycin) is provided as a model case. Evolutionary history analysis for each of the identified reversion alleles show that although reversion mutation accumulation biases seem to have occurred in certain strains, reversions to the allele present in a Methicillin-sensitive isolate (MSSA476) has occurred throughout the diversification of the lineage. In the case of the heml protein, only one protein copy in strain A6300 has acquired the reversion mutation shown. A second heml copy has acquired a Y→Y→D nonsynonymous mutation (not shown).

doi:10.1371/journal.pone.0056466.g002

Figure 2. Reversion RAMs accumulate in strains exposed to daptomycin and in one copy of a multicopy protein. Ancestor states for each reversion RAM were determined and mapped onto subspecies phylogenetic reconstructions as described in the methods using MEGA5. Nodes of the tree where mutations occurred in Parental-MRSA (P-MRSA) isolates from patients prior to exposure to daptomycin or vancomycin treatments [11,12] and reverted post-drug treatment to an allele also present in a Methicillin-Sensitive isolate (MSSA476) are annotated. A detailed evolutionary history for protein position 221 of the citZ protein in strain A8796 (treated with daptomycin) is provided as a model case. Evolutionary history analysis for each of the identified reversion alleles show that although reversion mutation accumulation biases seem to have occurred in certain strains, reversions to the allele present in a Methicillin-sensitive isolate (MSSA476) has occurred throughout the diversification of the lineage. In the case of the heml protein, only one protein copy in strain A6300 has acquired the reversion mutation shown. A second heml copy has acquired a Y→Y→D nonsynonymous mutation (not shown).

doi:10.1371/journal.pone.0056466.g002
Figure 3. Prevalence of non-reversion and reversion mutations in complex biosynthetic metabolic pathways. Reversion (A) and non-reversion mutations (B) identified in protein sequences from all MRSA isolates exposed to drug treatment were mapped by homology to the Staphylococcus aureus metabolome [31] (mutations in compounds acting in Nucleoside/nucleotide Biosynthesis (A, orange) and Amino Acid Biosynthesis (B, red) are shown). Compounds accumulating mutations interact in complex pathway networks that involve highly conserved proteins (solid lines) as well as “pathway-holes” (light grey lines) where identified sequence or functional homologs have not yet been identified in the Staphylococcus aureus genomes. The propensity of different mutant types to accumulate in distinct biological pathways, and significant correlation of reversions arising in strains exposed to daptomycin, is suggestive of how exposure to different drugs likely presents evolutionary adaptation biases in metabolic regulation in order to minimize fitness cost while promoting the progression of antibiotic resistance.

doi:10.1371/journal.pone.0056466.g003
were benign however, together their weighted scores gave a damaging prediction (Table 1). There were several cases of prediction conflict between PolyPhen and SIFT, which were more reliably resolved by implementation of CAROL rather than by selective filtering of sequence alignments (Methods, Table 1). Although in these cases, the instance of CAROL resolving to a deleterious prediction was less than 100% (Table 1). For humans, the frequency of nSNVs is directly correlated with evolutionary rate for a given position. The fastest-evolving positions are EPAs significantly more frequently than slower positions (81% vs. 53%, \( P < 0.01 \)) [25]. Disease associated mutations in humans are significantly associated with slower evolving positions and only a small fraction (<10%) are EPAs [25]. We find that all of the S. aureus positive control RAMs occur at slower evolving nucleotide positions, however, 30–40% of these positions are within codons that are evolving at a faster rate (Methods) [26].

Metabolic Regulators in Specific Biological Pathways Carry Reversion RAMs

A significant number of proteins carrying known RAMs are metabolic regulators. Interestingly, reversion mutations accumulate in enzymes mediating certain reactions of complex biosynthetic pathways whose intermediates are functionally involved with those that accumulate non-reversion mutations (Figure 3) [27]. The different reactions identified are involved in the following complex processes mediating the biosynthesis of: nucleosides/nucleotides, amino acids, aminoacyl-tRNA ("charged" tRNA), fatty acids and lipids, aromatic compounds, cofactors, prosthetic groups, and electron carriers (Figure 3). Specifically, reversion RAMs were identified in the adenylsuccinate synthetase and phosphoribosylamine-glycine ligase enzymes, both of which are involved in de novo biosynthesis of purines (Figure 3A).

Non-Reversion RAMs were not identified in enzymes primarily mediating nucleoside/nucleotide biosynthesis, but rather, accumulated in reactions central to amino acid synthesis (Figure 3B). It should be noted, however, that intrinsic to the nucleotide and amino acid biosynthetic metabolic processes are complex interconnected pathways that frequently share several key intermediates of reactions involving the transfer of nitrogen or one-carbon groups [28]. For example, purines and pyrimidines incorporate certain amino acids, or amino acid functional groups, and histidine synthesis requires part of a purine ring [28].

Enzymes with transferase activities required for amino group transfer (glutamate-1-semialdehyde-2,1-aminomutase) and amino acid metabolism (putative \( B\)-amino-7-oxononanoate synthase) also carry reversion RAMs (Figure 3A). UDP-N-acetylglucosamine 2-epimerase and citrate synthase II enzymes both carry multiple reversion RAMs. In bacteria, UDP-N-acetylglucosamine 2-epimerase enzymes catalyze the reaction producing UDP-ManNAc, which is critical to the formation of the antiphagocytic capsular polysaccharide in pathogens such as Streptococcus pneumoniae [29]. Citrate synthases catalyze a condensation reaction involving acetyl coenzyme A, an important intermediate molecule of the Krebs Cycle and precursor of lipids and steroids [28]. Likewise, non-reversion RAMs were identified in enzymes involved in other reactions mediating fatty acid and lipid metabolism (Figure 3).

Recent studies have shown that phospholipid synthesis in S. aureus accounts for their sensitivity to FASII inhibitors, which is unique in comparison to other pathogens such as S. pneumoniae [30].

Discussion

In response to drug treatment, it is known that bacterial pathogens acquire multiple non-synonymous mutations in proteins that either contribute directly to increasing virulence by promoting drug evasion or may act to lower the fitness costs of accumulating such variations (e.g. compensatory mutations) [7–9]. Our studies show that resistance associated mutations carried in either daptomycin or vancomycin insensitive isolates are in fact reversion mutations to alleles carried in a methicillin sensitive isolate. These reversion RAMs, therefore play a role (compensatory or otherwise) in mediating the continual progression of resistance to different antibiotic treatments. Our positive RAM control group does include reported compensatory mutations encoded by the agc, todB and walg genes [6,11]. Using our methods, two mutations in walh homologous protein sequences yielded different predictions regarding their functional relevance (Table 1). In a laboratory-derived strain exposed to vancomycin, a R263C mutation is predicted as damaging, whereas in a daptomycin-exposed strain the F471T change is benign. The variation that occurs at position 471 in the walk protein is a reversion to the MSSA476-allele. We also find that a K468Q RAM arising in the rpoB gene following daptomycin exposure is a reversion to the MSSA476-allele and is predicted as benign, in comparison to two RAMs in rpoB homologous translations that are accurately predicted as damaging in strains following either exposure to daptomycin or vancomycin (Table 1). Point mutations in the \( \beta \) subunit of RNA polymerase encoded by rpoB are known to render bacterial pathogens, such as S. aureus and Mycobacterium tuberculosis, resistant to rifampin treatment [31,32]. Similar to studies of E. coli, a recent study of rifampin-resistant clinical M. tuberculosis isolates has shown that compensatory evolution in other RNA polymerase subunits encoded by rpaB and rpoC, reduces fitness cost in comparison to their susceptible counterparts [9,33–35]. In both E. coli and M. tuberculosis, mitigation of the deleterious effects of a RAM by accumulation of compensatory mutations at independent sites has been established, however, it is not known whether these compensatory mutations are genetic reversions to more ancestral alleles present in the population [9,33].

Similar to agrC, it is possible that other reversion RAMs identified in our studies are also compensatory in function, or general suppressors that may reduce fitness costs, even though their role has mainly been previously described relative to the progression of resistance [11,12]. A previous study of clinical menadione-auxotrophic small-colony variant isolates of S. aureus that exhibit reduced gentamicin susceptibility, identified several sequence variations in the menB gene [36]. In one studied strain, growth-compensated mutants carrying genetic reversions and intragenic second-site mutations arose in the SCV population [36]. Compensatory roles of reversion mutations may also extend beyond one gene, or protein complex, and include functional pathways. For example, additional candidate compensatory mutations in S. aureus may include mutations in proteins with closely related dependencies in the same biological pathway (pgsA and chb2, Table 1). Or, may depend on more complicated interactions such as those we observe with the accumulation of reversion mutations in enzymes mediating certain reactions of complex biosynthetic pathways whose intermediates are functionally involved with those that accumulate non-reversion mutations (Figure 3). In addition, the significant correlation of reversions arising in strains exposed to daptomycin is suggestive of how exposure to a new antibiotic treatment may introduce reversion/non-reversion mutation acquisition biases in biological pathways important for fitness maintenance while promoting the progression of antibiotic resistance. It is unknown whether or not the reversion mutations identified by our studies also confer phenotypic sensitivity to antibiotics administered at an earlier stage of infection. In conclusion, future studies of RAMs in the context...
of evolution might therefore be applied to prioritize genetic variations for further clinical studies by profiling those that likely contribute to the progression of resistance by mediating adaptation to drug-exposure from reversion mutations acting to maintain the overall fitness of the organism. This type of approach would allow for the analysis of all predicted functional effects of genome-wide variations over the course of antibiotic treatments and therefore would be advantageous in comparison to current prediction methods. Our findings that adaptation to incremental drug exposures includes the accumulation of methicillin-sensitive reversion mutations suggest the potential effectiveness of select multi-drug cocktails that target both resistance and fitness during the course of *S. aureus* adaptation.

**Methods**

Positive and negative control groups of amino acid variations

A total of 47 amino acid variations previously identified as conferring lowered susceptibility or resistance of MRSA isolates following exposure to either vancomycin or daptomycin were used as positive controls for testing computational prediction algorithms [11,12] (Table I). A total of 21 nonsynonymous Single Nucleotide Variations (nSNVs) between Parental-MRSA (P-MRSA) isolates from patients prior to exposure to daptomycin or vancomycin treatments [11,12] and FPR3757 (MRSA) isolates at homologous positions not indicated by previous studies to mediate resistance were used as the negative control group for testing the efficacy of the prediction algorithms for bacterial mutations (Figure 1A–C).

Predicting the functional effects of amino acid variations

Amino acid variations identified in resistant clinical and laboratory isolates and the susceptible strain pair allele (reference sequence) were used to assay for damaging predictions (Table I). Additional and independent analysis runs were done using either the FPR3757 USA300 MRSA whole genome sequence corrected for sequencing errors [37], or the publicly available MSSA476 genome as a reference [38] (data not shown). Closely related homologous protein sequences were retrieved from the NCBI database (unfiltered) and aligned using MUSCLE [39]. Comparison PolyPhen predictions were also done using alignments of one representative sequence from each publicly available species of *Staphylococcus*, *Listeria*, *Macrococcus*, and *Bacillus* (filtered). Custom python scripts were used to run a prediction pipeline including PolyPhen, SIFT, and CAROL and predictions were calculated as described in [19–21]. Performance statistics for the three methods was done as described in [21] (Figure 1A), and using JROCFIT and JLABROC4 (Figure 1B), as well as customized R scripts for the ROCR package (Figure 1C) for comparative calculations of Receiver Operating Characteristic (ROC) curves [21,23].

**Evolutionary Rates and Phylogenetic Analysis**

Sequence alignments were used to assess overlap of homologous RAM positions and codons with 2- or 4-fold degenerate sites in MEGA5 [26]. Ancestral states for each reversion RAM were determined and mapped onto subspecies phylogenetic reconstructions using MEGA5 [26]. Genome alignments of homologous coding sequences were used to identify four-fold degenerate sites. These sites were used to build a tree using the Maximum Likelihood method based on the data specific model using MEGA5 [26,40]. The bootstrap consensus tree inferred from 1000 replicates is taken to represent the evolutionary history of the taxa analyzed. Unimetric branch lengths are shown to optimize visualization of ancestral relationships. Initial tree(s) for the heuristic search were obtained as described in the MEGA5 program [26]. A discrete Gamma distribution was used to model evolutionary rate differences among sites (5 categories (+G, parameter = 0.1000). The rate variation model allowed for some sites to be evolutionarily invariable (+I, 73.6551% sites). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis involved 10 nucleotide sequences. All positions containing gaps and missing data were eliminated. There were a total of 50460 positions in the final dataset. Evolutionary analyses were conducted in MEGA5 [26]. Homologous sequence alignments for each individual protein were mapped onto the subspecies tree to trace the ancestral states for the reversion RAMs.

**Acknowledgments**

The authors would like to thank members of The Microbial Sequencing Center at the Broad Institute of MIT and Harvard, and all of the members of Dr. Kumar’s lab for discussion of the work. We also thank Drs. Fabia Battistuzzi, Li Liu, and Alan Filipski for their critical review of the manuscript.

**Author Contributions**

Conceived and designed the experiments: MDC SK. Performed the experiments: MDC. Piloted customized PolyPhen prediction experiments: VG CE. Analyzed the data: MDC SK. Wrote the paper: MDC SK.

**References**

1. Kuhn G, Francioli P, Blanc DS (2006) Evidence for clonal evolution among highly polymorphic genes in methicillin-resistant *Staphylococcus aureus*. J Bacteriol 188: 169–178.
2. Katayama Y, Ito T, Hiramatsu K (2000) A new class of genetic element, *staphylococcus* cassette chromosome mec, encodes methicillin resistance in *Staphylococcus aureus*. Antimicrob Agents Chemother 44: 1549–1545.
3. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin intermediate *Staphylococcus aureus*. Clin Infect Dis 38: 448–451.
4. Cui L, Tominainga E, Neoh HM, Hiramatsu K (2006) Correlation between *Staphylococcus aureus* resistance to fusidic acid among clinical bacteremia isolates of *Staphylococcus aureus* Reversion RAMs in Metabolic Regulators.
5. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
6. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
7. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
8. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
9. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
10. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
11. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
12. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
13. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
14. Tajima F (1989) Statistical method for testing the neutral mutation hypothesis by DNA polymorphism data. Genetics 123: 585–595.
15. Zorzet A, Andersen JM, Nilsson AI, Møller NF, Andersson DI (2012) Compensatory mutations in agrC partly restore fitness in vitro to peptide deformylase inhibitor-resistant Staphylococcus aureus. J Antimicrob Chemother.

16. Besier S, Ludwig A, Brade V, Wichelhaus TA (2005) Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49: 1426-1431.

17. Subramanian S, Kumar S (2006) Evolutionary anatomies of positions and types of disease-associated and neutral amino acid mutations in the human genome. BMC Genomics 7: 396.

18. Kumar S, Dudley JT, Filipski A, Liu L (2011) Phylomedicine: an evolutionary telescope to explore and diagnose the universe of disease mutations. Trends Genet 1-10.

19. Sunyaev SR, Eisenhaber F, Rodchenkov IV, Eisenhaber B, Tumanyan VG, et al. (1999) PSIC: profile extraction from sequence alignments with position-specific counts of independent observations. Protein Eng 12: 387-394.

20. Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Research 11: 863-874.

21. Eng J (May 17 2006) ROC analysis web-based calculator for ROC curves. In: University BJH, editor. http://www.jrocfit.org. Accessed 2012 June 1.

22. Sing T, Randerath E, Beerenwinkel N, Lengauer T (2005) ROC: visualizing classifier performance in R. Bioinformatics 21: 3940–3941.

23. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, et al. (2012) Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Research 22: 735–745.

24. Reynolds MG (2000) Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156: 1471-1481.

25. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, et al. (2012) Comparison of the genetic basis for resistance to rifampicin in the Mycobacterium tuberculosis complex. Antimicrobial Agents and Chemotherapy 43: 1066-1069.

26. Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792-1797.

27. Nei M, Kumar S (2000) Molecular Evolution and Phylogenetics. New York: Oxford University Press.

28. Casali N, Nikolayevskyy V, Balabanova Y, Ignatyeva O, Kontsevaya I, et al. (2012) Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Research 22: 735–745.

29. Brandis G, Wranze M, Lijsa L, Hughes D (2012) Fitness-compensatory mutations in rifampcin-resistant RNA polymerase. Mol Microbiol 85: 142-151.

30. Highlander SK, Hultén KG, Qin X, Jiang H, Yerrapragada S, et al. (2007) Subtle genetic changes enhance virulence of methicillin-resistant and insensitive Staphylococcus aureus. BMC Microbiology 7: 99.

31. GeneDB The Staphylococcus aureus (MSSA476) homepage on GeneDB. http://www.genedb.org/Homepage/Saureus_MSSA476. Accessed 2012 June 1.

32. Nei M, Kumar S (2000) Molecular Evolution and Phylogenetics. New York: Oxford University Press.